Erythropoietin therapy and cancer related anaemia: Updated Swedish recommendations

Medical Oncology

Volumn 24, Issue 3, 2007, Pages 267-272

  Ahlqvist Rastad, Jane ^a   Albertsson, Maria ^b   Bergh, Jonas ^b   Birgegård, Gunnar ^c   Johansson, Peter ^d   Jonsson, Bertil ^a   Kjellen, Elisabeth ^e   Påhlman, Sven ^e   Zackrisson, Björn ^f   Österborg, Anders ^b  

^a MEDICAL PRODUCTS AGENCY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anemia; Cancer therapy; Epoetin; Erythropoietin; Erythropoietin receptor; Safety

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BREAST CANCER; CANCER; CANCER CONTROL; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL PRACTICE; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SWEDEN; SYSTEMATIC REVIEW;

ANEMIA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, ERYTHROPOIETIN; SURVIVAL ANALYSIS; SWEDEN; TREATMENT FAILURE;

EID: 36248997063     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-0037-5     Document Type: Article

References (22)

1. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362(9392):1255-60..
2. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4(8):459-60.
3. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24(29):4708-13.
4. Brown WM, Maxwell P, Graham AN, Yakkundi A, Dunlop EA, Shi Z, et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem cells (Dayton, Ohio) 2007;25(3):718-22.
5. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, et al. Anti-EPO receptor antibodies do not predict EPO receptor expression. Blood 2006;107(5):1892-5.
6. Kokhaei P, Abdalla AO, Hansson L, Kubbies M, Haselbeck A, Mikaelsson E, Jernberg-Wiklund H, Mellstedt H, Österborg A. Expression of erythropoietin receptor and in vitro functional effects of epoetin in B cell malignancies. Clin Cancer Res 2007;13(12):3536-44.
7. Aapro M, Barnadas A, Leonard R, Marangola M, Untch M, Ukarma L, Scherhag A, Burger HU. San Antonio Breast Cancer Symposium. Abstract, 2006.
8. Wright JU, Julian Y, Pritchard J, Whelan K, Smith T, Szechtman C, Roa B, Mulroy W, Rudinskas L, Gagnon L, Okawara B, Levine G, Randomized M. Double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1-6.
9. Aapro M, Coiffier B, Dunst J, Osterborg A, Burger HU. Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br J cancer 2006;95(11):1467-73.
10. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9,353 patients. J Natl Cancer Inst 2006;98(10):708-14.
11. Temkin SM, Hellmann M, Serur E, Lee Y-C, Abulafia O. Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gyn Cancer 2006;16(5):1855-61.
12. Azria D, Zouhair A, Serre A, Lemanski C, Schneider M, Ozsahin M, et al. Anemia in head and neck cancers. Bull Cancer 2005;92(5):445-51.
13. DAHANCA 10 http://frejacms.au.dk/dahanca/get_media. 2007.
14. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23(25):5960-72.
15. Michael U, Jackisch C, Lenhard MS, Du Bois A, Lueck HJ, Thomssen C, Kuhn W, Kurbacher C, Nitz R, Kreienberg R, Möbus VJ. Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dosedense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC). ASCO Annual Meeting. 2005;23(16S):Abstract 613.
16. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J. Natl Cancer Inst 2002;94(16):1211-20.
17. Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005;23(28):6941-8.
18. SCRIP. 2007;3237:20.
19. Antonadou D, Cardamakis E, Puglisi M, Malamos N. Erythropoietin anhances radiation treatment efficacy in patients with pelvic malignancies: final results of a randomised phase III study. Eur J Cancer 2001;37(suppl 6):144.
20. Blohmer J. Results with sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high-risk cervical cancer: Results of a prospective, randomized, open and controlled AGO and NOGGO-intergroup study. Ann Oncol 2004;15(Suppl 3):Abstract 447.
21. Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 2005;129(2):206-9.
22. Aranesp. 20010103 http://www.clinicalstudyresults.org. 2007.